Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors Life Science Investing
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma Life Science Investing
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference Pharmaceutical Investing
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference Life Science Investing
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer Life Science Investing
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Life Science Investing
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha -Thalassemia Life Science Investing
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel Life Science Investing
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference Life Science Investing
